The Honorable Rebecca F. Doherty, who is overseeing the federal Actos cases centralized in Louisiana, has appointed 19 plaintiffs’ attorneys to manage the litigation. As we have previously reported, recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer. A recent Bloomberg article stated that Takeda Pharmaceutical Company, the Asian-based manufacturer of Actos, could face upwards of 10,000 lawsuits in the United States. Eli Lilly & Company, which is also currently involved in the Darvocet litigation, has been named as a co-defendant based on allegations that the company withheld information from consumers about the associated risks and failed to provide adequate label warnings.
According to a March 12, 2012 note posted on the Court’s website, Judge Doherty advised that“[t]he Court has determined to effect the selection of lead counsel, liaison counsel, and plaintiffs’ executive and steering committees before the March 22nd- 23rd status conference.” The selection will allow for the plaintiffs’ attorneys to meet and confer while in Lafayette for the initial March conference.
If you feel you have experienced adverse side-effects from taking Actos, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.